Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

Lenka Bešše, Nan Li, Marianne Kraus, +8

Leukemia

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance

Ian Ferguson, Bonell Patiño-Escobar, Sami T. Tuomivaara, +26

Nature Communications

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Andrej Bešše, Sara Christina Stolze, Leo Rasche, +7

Leukemia

ImmunologyPathologyCarfilzomib ResistanceTumor BiologyMyeloid Neoplasia +15

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Bešše, Lenka Bešše, Marianne Kraus, +7

Cell chemical biology

Hematological MalignancyProteasome InhibitionOncologyMedicineMalignant Blood Disorder +9

Cytogenetics in multiple myeloma patients progressing into extramedullary disease

Lenka Bešše, Lenka Sedlaříková, Henrieta Grešlíková, +10

European Journal Of Haematology

Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis

Robert Brenig, Oltin T. Pop, Evangelos Triantafyllou, +16

Life Science Alliance

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

Dávid Vrábel, Lenka Sedlaříková, Lenka Bešše, +13

European Journal Of Haematology

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma

Lenka Bešše, Lenka Sedlaříková, Fedor Kryukov, +11

PLoS ONE

Hematological MalignancyNovel Putative MarkerOncologyAutoimmune DiseaseExtramedullary Myeloma +13

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

Felicitas Hitz, Marianne Kraus, Thomas Pabst, +11

Blood Cancer Journal

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

Johannes Kraus, Marianne Kraus, Nora Liu, +7

Cancer Chemotherapy and Pharmacology